Morningstar

Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference | Morningstar

“This year’s Calicivirus Conference will bring together the world's leading norovirus experts, making it the ideal venue to share our pan-viral protease inhibitor CDI-988 Phase 1 data and clinical ...

COCP: Phase 1b Norovirus Challenge Study of CDI-988 to Commence in 1Q26…

COCP READ THE FULL COCP RESEARCH REPORT Business Update Phase 1b Challenge Study of CDI-922 to be Initiated in 1H26 Cocrystal Pharma, Inc. (NASDAQ:COCP) is developing CDI-988 as a prophylaxis and ...
Business Insider

Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference

BOTHELL, Wash., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that President and co-CEO Sam Lee, PhD discussed the scientific foundation and clinical progress with ...
Virginia Connection Newspapers

Notorious Norovirus Stalks Region

It is winter, and a new strain of norovirus called GII.17[P17] is spreading across the U.S. including the northeast. MedStar Health Urgent Care in our region is experiencing an uptick in norovirus ...
CBS News

Spike in norovirus numbers not likely to end soon, Minnesota health officials say

Anthony Bettin is a web producer at CBS Minnesota. He primarily covers breaking news and sports, with a focus on the Minnesota Vikings. Esme Murphy, a reporter and Sunday morning anchor for WCCO-TV, ...
Nasdaq

Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference

BOTHELL, Wash., July 10, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that its first-in-class pan-viral protease inhibitor CDI-988 has been selected for an oral ...